| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF V600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
|
Dummer, Reinhard
|
|
|
21 |
3 |
p. 358-372
|
artikel
|
| 2 |
Adjuvant denosumab in early breast cancer
|
Peters, Niamh
|
|
|
21 |
3 |
p. e121
|
artikel
|
| 3 |
Adjuvant denosumab in early breast-cancer
|
de Boissieu, Paul
|
|
|
21 |
3 |
p. e123
|
artikel
|
| 4 |
Adjuvant denosumab in early breast cancer
|
Scimeca, Manuel
|
|
|
21 |
3 |
p. e122
|
artikel
|
| 5 |
Adjuvant denosumab in early breast-cancer
|
Fusco, Vittorio
|
|
|
21 |
3 |
p. e124
|
artikel
|
| 6 |
Adjuvant denosumab in early breast cancer – Authors' reply
|
Coleman, Robert
|
|
|
21 |
3 |
p. e125
|
artikel
|
| 7 |
Adjuvant therapy for melanoma: how to choose?
|
Karakousis, Giorgos
|
|
|
21 |
3 |
p. 319-320
|
artikel
|
| 8 |
Advancing the systemic therapy of lung cancer: quality or quantity?
|
Fung, Andrea S
|
|
|
21 |
3 |
p. 322-324
|
artikel
|
| 9 |
A new standard prophylaxis for emesis caused by cisplatin?
|
Celio, Luigi
|
|
|
21 |
3 |
p. e128
|
artikel
|
| 10 |
A new standard prophylaxis for emesis caused by cisplatin? – Authors' reply
|
Hashimoto, Hironobu
|
|
|
21 |
3 |
p. e129
|
artikel
|
| 11 |
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma
|
Romero, Joan Miguel
|
|
|
21 |
3 |
p. e126
|
artikel
|
| 12 |
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma – Author's reply
|
Geoerger, Birgit
|
|
|
21 |
3 |
p. e127
|
artikel
|
| 13 |
Cabozantinib: a new perspective for advanced bone sarcoma
|
Fagioli, Franca
|
|
|
21 |
3 |
p. 331-332
|
artikel
|
| 14 |
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
|
Italiano, Antoine
|
|
|
21 |
3 |
p. 446-455
|
artikel
|
| 15 |
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
|
Liang, Wenhua
|
|
|
21 |
3 |
p. 335-337
|
artikel
|
| 16 |
Capivasertib inhibits a key pathway in metastatic breast cancer
|
Nasrazadani, Azadeh
|
|
|
21 |
3 |
p. 318-319
|
artikel
|
| 17 |
CAR T cells: continuation in a revolution of immunotherapy
|
Singh, Anurag K
|
|
|
21 |
3 |
p. e168-e178
|
artikel
|
| 18 |
Cerebrospinal fluid evaluation in adult patients with medulloblastoma
|
von Bueren, André O
|
|
|
21 |
3 |
p. e120
|
artikel
|
| 19 |
Correction to Lancet Oncol 2016; 17: 287–98
|
|
|
|
21 |
3 |
p. e132
|
artikel
|
| 20 |
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
|
Christenson, Eric S
|
|
|
21 |
3 |
p. e135-e145
|
artikel
|
| 21 |
Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer
|
Westerveld, Henrike
|
|
|
21 |
3 |
p. e157-e167
|
artikel
|
| 22 |
EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?
|
Gholami, Sepideh
|
|
|
21 |
3 |
p. 324-326
|
artikel
|
| 23 |
Enfortumab vedotin shows promise in solid tumours
|
Burki, Talha Khan
|
|
|
21 |
3 |
p. e133
|
artikel
|
| 24 |
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy
|
Pala, Laura
|
|
|
21 |
3 |
p. e130
|
artikel
|
| 25 |
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy – Authors' reply
|
Gao, Jennifer J
|
|
|
21 |
3 |
p. e131
|
artikel
|
| 26 |
Extensive contamination with potential carcinogen prompts regulation across the USA
|
Alcorn, Ted
|
|
|
21 |
3 |
p. 340
|
artikel
|
| 27 |
Fertility preservation counselling for childhood cancer survivors
|
Demeestere, Isabelle
|
|
|
21 |
3 |
p. 329-330
|
artikel
|
| 28 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
|
Jones, Robert H
|
|
|
21 |
3 |
p. 345-357
|
artikel
|
| 29 |
Ireland's general election: new goals for cancer care?
|
The Lancet Oncology,
|
|
|
21 |
3 |
p. 317
|
artikel
|
| 30 |
Late morbidity and mortality in young survivors of cancer
|
Lähteenmäki, Päivi
|
|
|
21 |
3 |
p. 327-329
|
artikel
|
| 31 |
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study
|
Suh, Eugene
|
|
|
21 |
3 |
p. 421-435
|
artikel
|
| 32 |
Major disparities in public awareness of cancer
|
Burki, Talha Khan
|
|
|
21 |
3 |
p. 339
|
artikel
|
| 33 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, Lecia V
|
|
|
21 |
3 |
p. 373-386
|
artikel
|
| 34 |
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|
Garassino, Marina C
|
|
|
21 |
3 |
p. 387-397
|
artikel
|
| 35 |
Pazopanib as a choice for advanced solitary fibrous tumour
|
Lee, Alexander T J
|
|
|
21 |
3 |
p. 332-333
|
artikel
|
| 36 |
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial
|
Martin-Broto, Javier
|
|
|
21 |
3 |
p. 456-466
|
artikel
|
| 37 |
Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE)
|
Clark, Rebecca A
|
|
|
21 |
3 |
p. 436-445
|
artikel
|
| 38 |
Radiotheranostics: a roadmap for future development
|
Herrmann, Ken
|
|
|
21 |
3 |
p. e146-e156
|
artikel
|
| 39 |
Robot-assisted supermicrosurgery for lymphoedema
|
Gourd, Elizabeth
|
|
|
21 |
3 |
p. e134
|
artikel
|
| 40 |
Should patients who are incarcerated on death row receive palliative cancer care?
|
Oladeru, Oluwadamilola T
|
|
|
21 |
3 |
p. 337-338
|
artikel
|
| 41 |
Statistical significance and clinical evidence
|
Gates, Simon
|
|
|
21 |
3 |
p. e118
|
artikel
|
| 42 |
Statistical significance and clinical evidence – Authors' reply
|
Prasad, Vinay
|
|
|
21 |
3 |
p. e119
|
artikel
|
| 43 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
|
Bridgewater, John A
|
|
|
21 |
3 |
p. 398-411
|
artikel
|
| 44 |
Targeting MET in EGFR resistance in non-small-cell lung cancer—ready for daily practice?
|
Schmid, Sabine
|
|
|
21 |
3 |
p. 320-322
|
artikel
|
| 45 |
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
|
Eng, Cathy
|
|
|
21 |
3 |
p. 326-327
|
artikel
|
| 46 |
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
|
Pfeiffer, Per
|
|
|
21 |
3 |
p. 412-420
|
artikel
|
| 47 |
Trafficking of CAR T cells to sites of subclinical leukaemia cutis
|
O'Reilly, Maeve
|
|
|
21 |
3 |
p. e179
|
artikel
|
| 48 |
Working together to reduce the burden of pancreatic cancer
|
Landman, Allison
|
|
|
21 |
3 |
p. 334-335
|
artikel
|
| 49 |
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing
|
Hafez, Navid
|
|
|
21 |
3 |
p. 343-344
|
artikel
|
| 50 |
YOUTH: the sweatshirt collection created by adolescents with cancer
|
Bagliacca, Elena Pagani
|
|
|
21 |
3 |
p. 341-342
|
artikel
|
Tijdschrift beschrijving